Clinical Trials Browser

Platinum-Resistant Lung Small Cell Carcinoma × durvalumab × 90 days × Clear all

NCT04607954 2026-03-31

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Active not recruiting

Platinum-Resistant Lung Small Cell Carcinoma